Abstract:Antibodies perform both neutralizing and non-neutralizing effector functions that protect against certain pathogen-induced diseases. A human antibody directed at the SARS-CoV-2 Spike N-terminal domain (NTD), DH1052, was recently shown to be non-neutralizing, yet it protected mice and cynomolgus macaques from severe disease. The mechanisms of NTD non-neutralizing antibody-mediated protection are unknown. Here we show that Fc effector functions mediate NTD non-neutralizing antibody (non-nAb) protection against SARS-CoV-2 MA10 viral challenge in mice. Though non-nAb prophylactic infusion did not suppress infectious viral titers in the lung as potently as neutralizing antibody (nAb) infusion, disease markers including gross lung discoloration were similar in nAb and non-nAb groups. Fc functional knockout substitutions abolished non-nAb protection and increased viral titers in the nAb group. Fc enhancement increased non-nAb protection relative to WT, supporting a positive association between Fc functionality and degree of protection from SARS-CoV-2 infection. For therapeutic administration of antibodies, non-nAb effector functions contributed to virus suppression and lessening of lung discoloration, but the presence of neutralization was required for optimal protection from disease. This study demonstrates that non-nAbs can utilize Fc-mediated mechanisms to lower viral load and prevent lung damage due to coronavirus infection. COVID-19 has claimed over 6.8 million lives worldwide and caused economic and social disruption globally. Preventing more deaths from COVID-19 is a principal goal of antibody biologic and vaccine developers. To guide design of such countermeasures, an understanding of how the immune system prevents severe COVID-19 disease is needed. We demonstrate here that antibody functions other than neutralization can contribute to protection from severe disease. Specifically, the functions of antibodies that rely on their Fc portion were shown to confer antibody-mediated protection of mice challenged with a mouse adapted version of SARS-CoV-2. Mice given an antibody that could not neutralize SARS-CoV-2 still showed a decrease in the amount of infectious virus in the lungs and less lung damage than mice given an irrelevant antibody. The decrease in infectious virus in the lungs was even larger when the non-neutralizing antibody was engineered to more potently mediate non-neutralizing effector functions such as antibody-dependent cellular cytotoxicity. Thus, in the absence of neutralization activity, non-neutralizing binding antibodies can contribute to the overall defense against SARS-CoV-2 infection and COVID-19 disease progression.

Antibody-independent protection against heterologous SARS-CoV-2 challenge conferred by prior infection or vaccination

Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers

Vaccine-induced protection against SARS-CoV-2 requires IFN-γ-driven cellular immune response

Tissue resident memory T cells contribute to protectionagainst heterologousSARS-CoV-2 challenge

Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo

High-affinity, neutralizing antibodies to SARS-CoV-2 can be made without T follicular helper cells

Potently neutralizing and protective human antibodies against SARS-CoV-2

B cell maturation restored ancestral germlines to control Omicron BA.2.86

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern

Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions

Initial antigen encounter determines robust T-cell immunity against SARS-CoV-2 BA.2.86 variant three years later

Lung directed antibody gene transfer confers protection against SARS-CoV-2 infection

Strong SARS-CoV-2 N-Specific CD8+ T Immunity Induced by Engineered Extracellular Vesicles Associates with Protection from Lethal Infection in Mice

Antibodies elicited by SARS-CoV-2 infection and boosted by vaccination neutralize an emerging variant and SARS-CoV-1

Back to the Future: Immune Protection or Enhancement of Future Coronaviruses

Respiratory mucosal immunity against SARS-CoV-2 following mRNA vaccination

Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization

Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination

Mucosal immunity against SARS-CoV-2 variants of concern including Omicron following vaccination

Benefits of Repeated SARS-CoV-2 Vaccination and Virus-induced Cross-neutralization Potential in Immunocompromised Transplant Patients and Healthy Individuals